A047920 Stock Overview
A pharmaceutical company, researches and develops peptide drugs in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
HLB Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,700.00 |
| 52 Week High | ₩42,050.00 |
| 52 Week Low | ₩11,780.00 |
| Beta | 0 |
| 1 Month Change | -50.39% |
| 3 Month Change | -18.23% |
| 1 Year Change | 3.97% |
| 3 Year Change | -0.63% |
| 5 Year Change | 230.53% |
| Change since IPO | 96.25% |
Recent News & Updates
Shareholder Returns
| A047920 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -46.9% | 1.9% | 0.3% |
| 1Y | 4.0% | 8.8% | 6.0% |
Return vs Industry: A047920 underperformed the KR Pharmaceuticals industry which returned 8.8% over the past year.
Return vs Market: A047920 underperformed the KR Market which returned 6% over the past year.
Price Volatility
| A047920 volatility | |
|---|---|
| A047920 Average Weekly Movement | 17.7% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A047920's share price has been volatile over the past 3 months.
Volatility Over Time: A047920's weekly volatility has increased from 10% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Jae-hyeong Park | www.hlbpharma.co.kr |
HLB Pharmaceutical Co., Ltd., a pharmaceutical company, researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services.
HLB Pharmaceutical Co., Ltd. Fundamentals Summary
| A047920 fundamental statistics | |
|---|---|
| Market cap | ₩220.46b |
| Earnings (TTM) | ₩472.66m |
| Revenue (TTM) | ₩36.10b |
0.0x
P/E Ratio0.0x
P/S RatioIs A047920 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A047920 income statement (TTM) | |
|---|---|
| Revenue | ₩36.10b |
| Cost of Revenue | ₩18.06b |
| Gross Profit | ₩18.04b |
| Other Expenses | ₩17.57b |
| Earnings | ₩472.66m |
Last Reported Earnings
Dec 31, 2019
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A047920 perform over the long term?
See historical performance and comparison